login
  Password reminder
Spinal News
Contact the editor Visit Spinal News Twitter feed Visit Spinal News Facebook page
 

Alphatec comments on FDA’s letter regarding PureGen product for spinal fusion procedures


Thursday, 28 Jul 2011 12:26

Alphatec commented on the Food and Drug Administration’s (FDA) untitled letter that was sent to Parcell Laboratories on 23 June 2011 regarding Alphatec Spine’s PureGen osteoprogenitor cell allograft product for spinal fusion procedures for cervical and lumbar spine.


The FDA’s letter raised questions in connection with Parcell Laboratories’s position that the PureGen product is within the classification of human cell, tissue, and cellular or tissue-based products regulated solely under FDA’s regulation. 


Parcell Laboratories has responded to the FDA’s letter on 21 July 2011 with more complete information of the function of PureGen and how the product meets all of the criteria for being marketed under FDA’s regulation.   


Dirk Kuyper, Alphatec Spine’s president and CEO, stated, “Both Alphatec Spine and Parcell Laboratories are fully committed to work closely and collaboratively with the FDA to address the questions related to the PureGen product. We look forward to discussing the PureGen product with the FDA and sharing our clinical outcomes to date.”

 

About PureGen osteoprogenitor cell allograft

 

PureGen is a highly concentrated, pure population of adult stem cells that originates in bone marrow and is collected from live, healthy donors for optimal cell functionality. Unlike stem cell products that are currently commercially available, which have an unknown population of mesenchymal stem cells (MSCs) and are harvested from cadaveric donor tissue, PureGen delivers a similar potency of a pure adult MSCs without the need for cultural expansion.

 

The PureGen osteoprogenitor cell allograft was launched in October 2010 and has been successfully implanted in over 500 patients with no reported adverse events, complications or complaints. The product is used primarily in spinal fusion procedures for both cervical and lumbar spine. There are three controlled prospective studies currently underway to further establish the performance of the product by both academic and community-based spine surgeons.


To read FDA’s untitled letter please click here




Add New Comment

Most popular


Pain catastrophising may explain gender differences in pain and disability in lumbar spinal stenosis patients
Friday, 26 Sep 2014
A new study has found that women with lumbar spinal stenosis are more prone to pain catastrophising than men with the condition and this may explain why women report higher levels of pain and ... Pain catastrophising may explain gender differences in pain and disability in lumbar spinal stenosis patients

Long Bow expandable lateral interbody system receives FDA approval
Thursday, 25 Sep 2014
Life Spine has announced today that the FDA has given 510(k) marketing clearance for its Long Bow expandable lateral interbody system. Long Bow expandable lateral interbody system receives FDA approval

Zyga Technology receives CE mark approval for Glyder Facet Restoration Device
Wednesday, 29 Oct 2014
Zyga Technology has announced CE mark approval of the Glyder Facet Restoration Device, offering patients a long-term surgical treatment for low back pain caused by facet joint degeneration. Zyga Technology receives CE mark approval for Glyder Facet Restoration Device

Features


Recognising and managing sacroiliac joint pain
Monday, 27 Oct 2014
Spurred by newer treatment options and increased clinical research, it is increasingly recognised that 20–40% of low back pain complaints are generated from the sacroiliac joint. Steven R Garfin ... Recognising and managing sacroiliac joint pain

Intraspinal pressure monitoring improves management of patients with spinal cord injury
Thursday, 09 Oct 2014
Traumatic spinal cord injury is a devastating condition that mostly affects young men (about a third of whom will remain paralysed or wheelchair bound for the rest of their lives). In the USA, the ... Intraspinal pressure monitoring improves management of patients with spinal cord injury

Profiles


William C Watters III
Thursday, 06 Nov 2014
Initially intending to do a PhD in psychology, William C Watters III (clinical associate professor, ... William C Watters III

Lori Karol
Wednesday, 13 Aug 2014
Lori Karol, Texas Scottish Rite Hospital, Dallas, USA, talks to Spinal News International about the ... Lori Karol

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
 
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions